Loading...
The metabolic effects of proton-pump inhibitors (PPIs) on the cytochrome P450 system have been hypothesized to inhibit the antiplatelet activity of clopidogrel. Although recent studies have suggested that concurrent use of clopidogrel and PPIs is safe and effective for patients with cardiovascular disease (JW Gastroenterol Apr 2 2010), evidence about whether such inhibition of antiplatelet activity increases risk for adverse cardiovascular events has been mixed.
To examine this issue again, U.S. researchers retrospectively studied a cohort of 1033 enrollees in a multistate health insurance plan who had been discharged from the hospital after myocardial infarction (MI) or coronary stent placement and were subsequently treated with clopidogrel…